<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01377155</url>
  </required_header>
  <id_info>
    <org_study_id>DCC 03-11</org_study_id>
    <nct_id>NCT01377155</nct_id>
  </id_info>
  <brief_title>A Comparison of Two Initial Dosing Formulas</brief_title>
  <official_title>A Comparison of Two Initial Dosing Formulas for Basal Insulin in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diabetes Care Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diabetes Care Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate two methods of starting basal insulin to see which method may
      achieve a faster-to-goal titration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current recommended starting dose of basal insulin in type 2 diabetes is either a fixed
      dose, e.g. 10 U, or a weight-based formulas, 0.1-0.2 U/kg. The estimate of eventual titration
      dose to attempt to reach a fasting glucose goal is 0.49 U/kg. Those many weeks of dosage
      upward titration are required. The investigators propose to compare the current recommended
      weight based, 0.1 U/kg to a correction factor derived formula. Starting with an insulin
      tolerance test estimation of basal dose, one would arrive at the eventual titrated basal
      insulin dose in significantly less days than starting at a starting dose estimate of 0.1
      U/kg. Further, there would be no significant increase in overall reported hypoglycemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days to reach the titration target</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of days for the subject to reach the titration target blood sugar of 110 ml/dl</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The frequency of reported and documented (&lt;70 mg/dl) hypoglycemic events per 24 hour period</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin determir</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin detemir</intervention_name>
    <description>Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.</description>
    <arm_group_label>Insulin determir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes

          2. Age 18 years and above

          3. Concurrently on ± sulfonylureas ± thiazolidinedione ± DDP IV inhibitors ± metformin ±
             glinides

          4. A1c ≥ 7.0% but ≤ 10%

          5. Capable of self monitoring glucose ≥4/day

          6. Previously compliant with clinical recommendations

          7. Fasting blood glucose ≥ 150 mg/dl

          8. BMI ≤ 45 kg/m2

        Exclusion Criteria:

          1. Urinary ketosis

          2. Currently or expected alteration in insulin sensitivity such as major surgery,
             infection, renal failure (creatinine &gt;1.5 mg/dl), glucocorticoid treatment, recent
             (within 2 weeks) serious hypoglycaemic episode (requires assistant of another)

          3. Currently participating in another clinical trial

          4. Known or suspected allergy to insulin determir

          5. Using insulin

          6. Pregnancy or nursing or the intention of becoming pregnant or not using adequate

          7. Significant liver or heart failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen B King, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Care Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Care Center</name>
      <address>
        <city>Salinas</city>
        <state>California</state>
        <zip>93901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2011</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diabetes Care Center</investigator_affiliation>
    <investigator_full_name>Allen B. King, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>basal insulin</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>diabetes mellitus type two</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

